<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00403988</url>
  </required_header>
  <id_info>
    <org_study_id>L_9116</org_study_id>
    <nct_id>NCT00403988</nct_id>
  </id_info>
  <brief_title>Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma</brief_title>
  <official_title>A Clinical Phase II Study of Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin®) in Advanced Breast Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>American University of Beirut Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>American University of Beirut Medical Center</source>
  <brief_summary>
    <textblock>
      Study Objective :

      To assess the efficacy and the safety of the combination of Oxaliplatin, and Vinorelbine with
      or without Trastuzumab as a salvage regimen in patients with Metastatic Breast Cancer
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The results of a same study design have shown low response with important side effects.
    Accordingly &amp; ethicly, the study has been stopped.
  </why_stopped>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>During the Study Conduct</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>time to progression (TTP).</measure>
    <time_frame>during the study conduct</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>survival</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tolerance</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity.</measure>
    <time_frame>During the study conduct</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Breast Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Metastatic, histologically or cytologically proven breast cancer.

          -  At least one bi-dimensionally measurable lesion.

          -  Previous treatment with chemotherapy as first line for metastatic disease is mandatory
             especially with anthracyclines +/- the Taxanes.

          -  Treatment as adjuvant is allowed.

          -  World Health Organization-ECOG performance status 0-2.

          -  Adequate renal function (Creatinine &lt;= 1.4 or Creatinine clearance &gt;= 30 ml/min)

          -  Adequate hepatic function (Liver Function Tests not more than 3 times the normal
             values)

          -  Adequate bone marrow reserve is required (Neutrophils (PMN) &gt;= 2000/mm2 and Platelets
             &gt;= 100,000/mm2)

          -  Patient who will receive Herceptin should have an over-expression of HER2-neu.

        Exclusion Criteria:

          -  Symptomatic peripheral neuropathy (National Cancer Institute common toxicity criteria
             grade more than one).

          -  Pregnant or breast-feeding.

          -  History of prior malignancies (with the exception of excised cervical
             carcinoma-in-situ or non-melanoma cell skin carcinoma).

          -  Receiving or had received, any treatment with experimental drugs.

          -  Had known brain or leptomeningeal involvement.

          -  Had a serious medical condition like congestive heart failure or an Ejection Fraction
             ≥ 40 %.

          -  The presence of bone as a sole site of metastasis.

          -  Radiation therapy to all areas of measurable disease less than four weeks before
             treatment.

          -  Creatinine two times above the normal range

          -  Hypercalcemia

          -  Evaluable but not a measurable disease as a sole site of metastasis: pleural effusion
             - Ascites - Pericardial effusion.

          -  Concomitant steroid intake for &gt; 4 weeks

          -  Bilirubin two times above the normal range

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AmericanUBMC</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2006</study_first_submitted>
  <study_first_submitted_qc>November 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2006</study_first_posted>
  <last_update_submitted>November 3, 2008</last_update_submitted>
  <last_update_submitted_qc>November 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2008</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

